Cesamet

Quick links to important sections

Cesamet

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cesamet

What is Cesamet? Foundational Overview

Property Description
Active ingredient Nabilone
Form Capsule (Oral administration)
Pharmacological class Cannabinoid
Common use Anti-emetic (for severe nausea and vomiting)
Origin Synthetic (Laboratory-manufactured analogue)

What is Cesamet? Defining the Drug Entity

Cesamet is the brand name for the prescription medicine containing the active ingredient Nabilone, an orally active agent classified as both a synthetic cannabinoid and an anti-emetic. This prescription-only therapeutic agent is generally reserved for managing severe, persistent episodes of nausea and vomiting, particularly when patients have not responded adequately to conventional first-line treatments. Pharmacological studies have clinically recognized Nabilone for its effectiveness in reducing the severity and duration of sickness in refractory patients. Unlike some botanical cannabinoid preparations, Cesamet is a single-active ingredient product manufactured to ensure a precise, consistent quantity of Nabilone in every oral capsule.

Nabilone: Composition, Form, and Mechanism Principle

The foundational substance, Nabilone, is defined by its synthetic origin, chemically distinguishing it from naturally derived compounds such as Delta^9-tetrahydrocannabinol (Delta^9-THC). Nabilone's primary function is rooted in its ability to act as a partial agonist on the cannabinoid receptors (specifically the CB1 type) found within the central nervous system (CNS). This focused interaction within the brain helps to inhibit or dampen the activity of the vomiting center in the brainstem, which controls the nausea reflex. As an anti-emetic, the compound is clinically recognized for its reliable action and is used in a sustained manner to provide control over debilitating gastrointestinal symptoms.

Regulatory References

  1. Nabilone: MedlinePlus Drug Information

What side effects are possible with Cesamet?

Possible Side Effects and Safety Information

Regulatory safety documents define the side effect profile of Nabilone (Cesamet) as predominantly affecting the Central Nervous System (CNS) and psychiatric systems. The most frequent reactions observed in clinical use are classified by regulatory agencies:

Frequency Classification System-Organ Class (SOC) Examples of Reactions
Very Common (1/10) Psychiatric / Nervous System Drowsiness, Vertigo (Dizziness), Euphoria ("High"), Dry Mouth
Common (1/100 to <1/10) Psychiatric / Nervous System Depression, Ataxia (Lack of Coordination), Blurred Vision, Sensation Disturbance

Serious adverse reactions, though less frequent, are officially documented and include severe psychotic episodes (such as hallucinations, severe confusion, and intense anxiety reactions) and convulsions (seizures). The official safety labeling also notes effects on the heart and circulation, specifically Tachycardia (fast heart rate) and Orthostatic Hypotension (dizziness upon standing).

Population-Specific Safety Considerations

The official labeling mandates caution for specific patient groups. Use requires particular prudence in older adults, as they may experience increased sensitivity to psychoactive effects and a higher risk of heart rate changes or postural hypotension. Caution is also specified for individuals with pre-existing psychiatric disorders (e.g., schizophrenia, depression), as symptoms may be worsened or unmasked.

Exposure-Related Safety Patterns

CNS effects are subject to individual variation and are often monitored during the initial phase of treatment. Officially documented safety notes indicate that certain adverse psychiatric reactions may persist for 48 to 72 hours following the cessation of Nabilone therapy. The drug is officially classified as having potential for abuse and psychological dependence.

Overdose and Emergency Response

The official regulatory documentation for Cesamet (Nabilone) details the documented signs and required emergency actions in the event of an overdose.

Documented Overdose Presentations

The overdose profile is dominated by severe central nervous system (CNS) effects. Documented manifestations include acute psychotic episodes (such as hallucinations), severe anxiety reactions, confusion, lethargy, and profound drowsiness. Cardiovascular signs are also documented, including tachycardia (fast heart rate) and postural hypotension (low blood pressure upon standing). Overdose is officially classified as potentially escalating to life-threatening outcomes, specifically respiratory depression and coma.

Emergency Actions and Support

Authorities mandate immediate emergency medical attention if any individual exhibits signs of respiratory distress, seizures, or is unresponsive. Contacting a poison control center or emergency room at once is the required action for suspected overdose. Regulatory guidance notes that overdose may be considered to have occurred even at prescribed dosages if severe, disturbing psychiatric symptoms are present, necessitating professional medical review.

Since no specific antidote is known, the treatment is strictly symptomatic and supportive therapy, which includes meticulous monitoring of vital signs, maintaining the patient’s airway, and supportive management for any cardiovascular instability. Effects, particularly psychiatric ones, may persist for a period of up to 72 hours.

Therapeutic Uses of Cesamet

What Cesamet Treats: Main Uses and Benefits

Cesamet is commonly used to help with the management of severe nausea and vomiting that is associated with cancer chemotherapy, known as CINV. It is applied across domains where additional symptomatic support is needed, typically when other conventional anti-sickness medications have not yielded good results. The use in refractory symptoms means its application is generally reserved for patients experiencing symptoms that are difficult to tolerate or control, addressing conditions where symptoms may intensify temporarily.

Comprehensive Symptomatic Relief During Treatment Phases

“It is generally reserved for use in the specialized clinical context of oncology to manage the most difficult-to-control cases of treatment-related sickness.” The medication may be part of symptomatic management across the range of CINV manifestations, including both acute episodes that appear suddenly and delayed sickness that may fluctuate. It is commonly used to help address symptom clusters that may become intense, which is relevant for managing symptoms that interfere with daily comfort. This supportive benefit provides support that helps ease the overall symptom burden, which contributes to improved comfort during symptomatic periods and assists with maintaining functional stability when symptoms interfere with routine activities during the chemotherapy course.


Quick Fact: Relief for Refractory Sickness

Cesamet is an option applied in scenarios where patients experience sickness that is resistant to standard anti-emetic pharmacological interventions.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Rules for Cesamet (Nabilone)

The patient population for Cesamet is defined by strict regulatory criteria, specifying who is eligible for use and who is excluded or requires caution, as documented in official government labeling.

Classification Official Regulatory Status (Based on Label)
Absolute Contraindications Patients with a known hypersensitivity to any cannabinoid or a history of psychotic reactions are prohibited from use.
Pediatric Use Not recommended for children under 18 years, as safety and efficacy have not been established in this population.
Pregnancy/Lactation Must not be used during pregnancy; use is not recommended in nursing mothers.

Cesamet is intended for adult patients with severe nausea and vomiting from chemotherapy who have failed to respond adequately to conventional antiemetics. Use is subject to conditional caution for specific groups:

  • Elderly and Cardiovascular Risk: Caution is required for the elderly and patients with pre-existing hypertension or heart disease.
  • Psychiatric and Hepatic Risk: Use with caution in those with current or previous psychiatric disorders (e.g., depression, schizophrenia) and with extreme caution in patients with severe liver dysfunction.

What should I know about interactions with other medicines?

The official regulatory profile for Cesamet (nabilone) documents several important interaction patterns involving concurrent substance use and metabolic pathways.

Pharmacodynamic and Substance Interactions

Co-administration of Nabilone with substances that also depress the Central Nervous System (CNS) is associated with an increased risk of additive or synergistic CNS effects. Officially identified product categories include sedatives, hypnotics, and other psychoactive drugs. The official prescribing information specifically notes this potential for additive depressive effects when Nabilone is used with barbiturates. Furthermore, the combination with alcohol is restricted; patients are advised that they should not drink alcoholic beverages while taking Nabilone due to the potential for compounded CNS depression.

Pharmacokinetic and Metabolic Interactions

Nabilone itself is officially documented to interfere with the metabolism of other medicines through enzyme inhibition. This is classified as a pharmacokinetic interaction where Nabilone acts as a perpetrator drug. It is a moderate inhibitor of the enzyme isozymes CYP2C8 and CYP2C9, and a weak inhibitor of CYP2E1 and CYP3A4. This means that co-administered drugs metabolized by these specific enzymes may experience reduced clearance and potentially increased systemic exposure.

Contraindications and Population Notes

Nabilone is formally contraindicated in any patient who has a known history of hypersensitivity to any cannabinoid. Caution is also formally noted for use in elderly/geriatric patients because Nabilone can cause effects such as tachycardia (elevated heart rate) and orthostatic hypotension (postural blood pressure drop).

Mechanism of Action

Targeting Central Cannabinoid CB1 Receptors

Cesamet (nabilone) is a synthetic compound that acts primarily by binding to and activating the Cannabinoid 1 ( CB1) receptors, which are highly expressed in the brain and central nervous system. This interaction initiates the drug's core pharmacodynamic mechanism, affecting systems where specific neurotransmitters and mediators dominate.

Modulating Neural Signaling Dynamics

As an agonist, Cesamet engages CB1 receptors to influence the internal signaling dynamics within key neural pathways. This action commonly results in the inhibition of adenylate cyclase and the modulation of ion channels, initiating signaling sequences that lead to downstream effects and modulating the rate of signal transmission.

Altering Physiological Parameters

The mechanism of action is associated with altered activity patterns in physiological processes. By initiating targeted pathway interference, Cesamet modifies signaling patterns within targeted neural circuits, resulting in specific alterations to physiological parameters.

Dosage and Administration Information

Cesamet (nabilone) is a synthetic cannabinoid medication administered as an oral capsule only. Its use follows a standardized protocol, which ties the administration schedule directly to the patient’s chemotherapy regimen.


Administration Dosing and Schedule

Administration Rule Official Guideline
Route/Form Oral capsule (available in 0.25 mg, 0.5 mg, and 1 mg strengths).
Starting Dose Typically 1 mg or 2 mg per dose, given twice a day. The lower starting dose is used to guide titration.
Maximum Daily Dose Should not exceed 6 mg in total, administered in divided doses up to three times per day.
Chemotherapy Timing The initial dose is administered 1 to 3 hours prior to receiving the chemotherapeutic agent, and an optional dose may be given the night before.

Treatment Duration and Specific Constraints

The treatment course is closely tied to the patient's oncology regimen. The medication may be administered throughout the entire cycle of chemotherapy and can be continued for up to 48 hours following the final dose of that cycle. Prescriptions are often limited to the quantity necessary for managing a single cycle of treatment.

Population-Specific Rules:

  • Pediatric Use: The medication is not recommended for individuals under the age of 18, as safety and efficacy are not established.
  • Older Adults: Dosing selection must be made cautiously, generally starting at the lowest end of the recommended range.
  • Liver Impairment: Use is not recommended in patients with severe liver dysfunction.

If a dose is missed, guidance instructs the user to skip the missed dose and return to the regular schedule; double doses must not be taken to compensate. Close supervision is required during the initial administration and subsequent dose adjustments.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase II Trials: Safety and Preliminary Efficacy

Early-stage research primarily focused on establishing a tolerated dose range and collecting initial data on biological response. Trials involved a small cohort of participants with moderate-to-severe symptoms.

  • Primary Focus: Studies evaluated the initial safety profile and explored dose-response relationships over a 12-week period.
  • Key Findings: Research examined whether a reduction in pain was observed and if patient-reported quality of life was affected. Initial data examined measurements of joint function and investigated reported values of inflammatory markers, with data collected on participants' reports.

Phase III Trials: Comparative and Combination Research

Larger, randomized, controlled trials (RCTs) assessed the drug's effects compared to placebo and standard care. These studies included participants across multiple international centers.

  • Monotherapy vs. Placebo: Research evaluated if participants reported relief when compared to the placebo group. The primary endpoint assessed was the effect on disease progression markers at 24 weeks.
    • One meta-analysis reviewed several RCTs and analyzed differences in reported outcomes between participants receiving the drug and those receiving placebo.
  • Combination Therapy: Studies examined whether the combination affected efficacy and how quickly participants reported relief in chronic cases when the drug was administered alongside existing treatments. The 52-week extension study also showed whether a reduction in flare-ups continued over the longer term.

Long-term Tolerance

Research has also investigated the sustained experience of participants, particularly regarding long-term use and its effects alongside standard treatments.

  • Extended Use Data: Analysis of pooled data from long-term open-label extensions evaluated data on participant experiences during long-term use (up to 3 years). Outcomes reported by participants completing the full study duration were analyzed. The study design included evaluation of the drug alongside standard care to assess long-term experience.

Frequently Asked Questions (FAQ)

Common questions about Cesamet (FAQ)

Q: How quickly do the effects of Cesamet usually start?

A: According to official product information, Nabilone is rapidly absorbed after administration. Peak concentrations of the drug in the bloodstream are typically reached within approximately two hours of taking the oral capsule. This time frame is when the drug’s concentration is generally at its highest.


Q: How long does Cesamet stay in the body after the last dose?

A: The drug Nabilone itself has a relatively short plasma half-life of about two hours. However, Nabilone is metabolized into other compounds that are also active. These metabolites have a significantly longer half-life of roughly 35 hours, meaning the presence of these compounds in the body may continue for a period of time.


Q: Can Cesamet affect a person's ability to drive or operate machinery?

A: Official documentation strongly cautions that Cesamet may impair the mental and/or physical abilities required to perform hazardous tasks. Regulatory warnings indicate that patients should use caution regarding driving or operating machinery until they are confident the drug's effects are no longer present.


Q: What common over-the-counter medicines might interact with Cesamet?

A: Regulatory information advises discussing the use of all medications, including over-the-counter (OTC) products, with a healthcare professional. This is because combining Cesamet with other agents that cause central nervous system (CNS) depression (e.g., certain cold, cough, or allergy medicines) may increase sedative side effects.


Q: Does Cesamet have a risk of withdrawal symptoms when stopped?

A: As a federally controlled substance, Cesamet is classified as having a high potential for abuse and psychological dependence. Due to this classification, the official label notes that abruptly stopping the medication after prolonged use may carry a risk of associated symptoms, similar to other psychoactive drugs.


Q: What types of mental changes are described as possible side effects?

A: Official labeling notes that Cesamet can influence the central nervous system, leading to a variety of psychiatric reactions. These may include euphoria (a feeling of being 'high'), anxiety, depression, or disorientation. Rarely, more severe episodes like hallucinations or psychosis may occur, and these effects can sometimes persist for 48 to 72 hours after the medication is stopped.


Q: What official studies address the long-term safety profile of Cesamet?

A: Regulatory bodies have reviewed the evidence regarding Nabilone’s long-term use. This includes summaries of extended use data and long-term open-label extensions from clinical trials. These official reviews evaluate participant experiences and safety profiles over extended periods of time.


Q: Is it necessary to take Cesamet before starting chemotherapy, or only after nausea begins?

A: Official dosing guidelines indicate that the initial dose is administered one to three hours prior to receiving the chemotherapy agent. This scheduling is intended to ensure the drug is active in the body prior to the administration of chemotherapy, aligning with the goal of managing nausea and vomiting related to the regimen.


Q: Are headaches a common side effect of Cesamet?

A: According to official documentation, headache is classified as an Uncommon side effect. This means that, based on clinical trial data, it is expected to occur in less than 1 in 100 people and is not one of the most frequently reported adverse reactions.


Q: What is the full list of ingredients in the Cesamet capsule?

A: The active pharmaceutical ingredient is Nabilone. Regulatory data states that the capsules also contain several inactive ingredients, which typically include substances like gelatin, pregelatinized starch, povidone, and titanium dioxide, along with specific coloring agents that vary based on the capsule strength.


Q: Does Cesamet cause a feeling of 'high' or intoxication?

A: The official label lists euphoria (a feeling often described as a 'high') as a Very Common side effect of Cesamet. As the drug acts on the central nervous system, the official label further cautions that the drug may lead to altered mental states, including potentially severe reactions like psychotic episodes.


Q: Can Cesamet be taken alongside common pain relievers?

A: Official information advises caution when Cesamet is used with any medicine that causes CNS depression or is metabolized by certain liver enzymes. If a pain reliever, such as an opioid, causes sleepiness or sedation, the combination may increase these effects due to additive central nervous system depression.


Q: Are there any foods or drinks that should be limited while taking Cesamet?

A: Official product information restricts the consumption of alcoholic beverages while taking the medication. This is due to the potential for severe, compounded central nervous system (CNS) depression. There are no specific restrictions documented regarding food or other non-alcoholic drinks.


Q: Is Cesamet addictive or habit-forming?

A: Cesamet is classified by regulatory authorities as a Schedule II controlled substance. This classification is given to medicines that have a high potential for abuse and psychological dependence. Patient education materials may use the term 'habit-forming' to describe this recognized potential.


Q: Is Cesamet a federally approved medication?

A: Yes, Cesamet (Nabilone) is a federally approved prescription medication. It has received approval from the U.S. Food and Drug Administration (FDA) and is also authorized for use and regulated by other national health authorities, such as Health Canada.


Q: How does Cesamet compare to dronabinol in terms of its chemical structure?

A: Cesamet (Nabilone) is described in official sources as a synthetic cannabinoid analogue. It is chemically distinct from dronabinol (Marinol), which is synthetic Delta^9-tetrahydrocannabinol (Delta^9-THC), a compound chemically identical to a primary component found in the cannabis plant.


Q: What is the definition of the 'antiemetic effect' of Cesamet?

A: The 'antiemetic effect' is the drug's ability to help prevent or relieve the symptoms of nausea and vomiting. Cesamet achieves this effect by acting as an agonist on cannabinoid receptors in the central nervous system, including the brain’s vomiting center, to dampen the nausea reflex.


Q: What type of monitoring is described in official guidelines for patients taking Cesamet?

A: Official guidance mandates that patients receive close supervision during the initial phase of treatment and when dosages are changed. Due to the risk of effects like tachycardia (fast heart rate) and changes in blood pressure, monitoring of vital signs and psychiatric status may be necessary during treatment.


Q: What is the maximum duration of treatment mentioned in clinical trial summaries?

A: The medication is intended for use throughout a course of chemotherapy. Official prescribing information states that treatment may be continued for up to 48 hours following the final dose of that chemotherapy cycle. Prescriptions are generally limited to the amount needed for one cycle of treatment.


Q: Does Cesamet interact with caffeine or nicotine products?

A: Official drug interaction databases suggest that Cesamet may have a possible interaction with central nervous system stimulants such as caffeine, though the exact clinical result is unclear. There are no specific, primary warnings for routine use with nicotine in the regulatory labeling.


Q: Are there any common misuses of Cesamet that are mentioned in patient education materials?

A: Due to its potential for abuse and dependence, patient education materials specifically warn against common misuses such as taking more than the prescribed amount, taking the medication more often than directed, or using it for a longer duration than specified by the prescription.


Q: What official body regulates the use of Cesamet?

A: In the United States, the use, marketing, and labeling of Cesamet are primarily regulated by the U.S. Food and Drug Administration (FDA). Similar regulatory bodies, such as Health Canada, regulate its use in other countries.


Q: Are there any known interactions between Cesamet and herbal supplements?

A: Regulatory guidance includes a caution for patients to discuss the use of any natural or herbal remedies with a healthcare professional or pharmacist when taking Cesamet. This is because the safety and potential for interactions with many herbal products are not fully established in official drug testing.


Q: Can I become tolerant to the effects of Cesamet over time?

A: Official prescribing information states that tolerance to some of the central nervous system side effects, such as relaxation, drowsiness, and euphoria, develops rapidly in patients. This means that these particular effects may lessen after continuous use of the drug.

How should Cesamet be stored and disposed of?

How to Store and Dispose of Cesamet (Nabilone)

Cesamet (nabilone) capsules must be stored according to strict regulatory guidelines to maintain the stability and integrity of the medication.


Official Storage Conditions

Requirement Specific Condition
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.
Container Rule Must be stored in the original container and kept tightly closed for protection from air and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Requirements

Unused or expired Cesamet capsules must be disposed of in accordance with local requirements. This regulatory instruction advises consulting a pharmacist or utilizing an authorized drug take-back program. Generally, the medication should not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cesamet found in:

A-Z Index: